特应性皮炎中靶向抗葡萄球菌的内溶素治疗及其对激素使用、疾病严重程度和微生物组的影响:随机对照试验研究方案(MAAS试验)
MAAS试验为多中心、安慰剂对照、双盲、随机优效性平行组研究,纳入100例18岁及以上中重度特应性皮炎患者,先以0.1%曲安奈德乳膏进行2周导入期标准化激素使用,随后随机接受Staphefekt乳膏或安慰剂治疗12周并随访8周,主要比较两组每周使用激素乳膏天数的差异。
要点
- Staphefekt为工程化噬菌体内溶素,特异性杀灭金黄色葡萄球菌而不伤害其他皮肤共生菌。
- 主要结局为Staphefekt组与安慰剂组每周使用曲安奈德乳膏天数的差异。
- 次要结局包括激素用量(克)、临床疗效、生活质量、微生物组成及安全耐受性。
核心结论
- 该试验结果将提供长期抗葡萄球菌治疗对中重度特应性皮炎患者激素使用、临床症状和生活质量影响的数据。
- 关于皮肤微生物组(包括金黄色葡萄球菌)生长特征的额外数据将有助于了解微生物组在特应性皮炎病理生理中的作用。
研究设计与样本
- 多中心、安慰剂对照、双盲、随机优效性平行组试验,共纳入100例18岁及以上、诊断为中重度特应性皮炎且在入组前数周使用外用糖皮质激素的参与者。
- 研究在鹿特丹Erasmus MC大学医学中心与鹿特丹Havenziekenhuis合作开展。
- 经过2周导入期以0.1%曲安奈德乳膏标准化激素使用后,参与者随机接受含Staphefekt的 cetomacrogol 基质乳膏或安慰剂治疗12周,随后随访8周。
关键数值与推荐
- 主要目标为评估Staphefekt组与安慰剂组在激素联合治疗需求上的差异,以每周使用激素乳膏(曲安奈德)的天数衡量。
- 次要结局包括以克衡量的激素乳膏用量差异、临床疗效、生活质量、微生物组成(包括金黄色葡萄球菌)以及安全性和耐受性方面的差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atopic dermatitis (AD) is associated with reduced skin microbial diversity and overgrowth of Staphylococcus (S.) aureus. However, the importance of S. aureus colonisation in the complex pathogenesis remains unclear and studies on the effect of anti-staphylococcal therapy in non-infected AD show contradictory results. Long-term interventions against S. aureus might be needed to restore the microbial balance, but carry the risk of bacterial resistance induction. Staphefekt, an engineered bacteriophage endolysin, specifically kills S. aureus leaving other skin commensals unharmed. Bacterial resistance towards endolysins has not been reported, nor is it expected, which allows us to study its effect as long-term anti-staphylococcal treatment in non-infected AD. METHODS: This is a multi-centre, placebo-controlled, double-blinded and randomized superiority trial with a parallel group design. A total of 100 participants, aged 18 years or older, diagnosed with moderate to severe AD and using a topical corticosteroid in the weeks before enrolment are included in the study. The study is executed in the Erasmus MC University Medical Centre Rotterdam in collaboration with the Havenziekenhuis Rotterdam. After a 2-week run-in period to standardize the corticosteroid use with triamcinolone acetonide 0.1% cream, participants will be randomized to either treatment with Staphefekt in a cetomacrogol-based cream or a placebo for 12 weeks, followed by an 8-week follow-up period. The primary objective is to assess the difference in the need for corticosteroid co-therapy between the Staphefekt and the placebo group, measuring the number of days per week of corticosteroid cream (triamcinolone) use. Secondary outcomes include the difference in use of corticosteroid cream measured in grams, differences in clinical efficacy, quality of life (QoL), microbial composition (includi23ng S. aureus) between the Staphefekt and the placebo group, and the safety and tolerability. DISCUSSION: The results of this trial will provide data about the effect of long-term anti-staphylococcal therapy with Staphefekt on corticosteroid use, clinical symptoms and QoL in patients with moderate to severe AD. Additional data about growth characteristics of the skin microbiome, including S. aureus, will give insight into the role of the microbiome as a factor in the pathophysiology of AD. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02840955 . Registered on 11 July 2016.
引用
- Totté J, de Wit J, Pardo L, et al. Targeted anti-staphylococcal therapy with endolysins in atopic dermatitis and the effect on steroid use, disease severity and the microbiome: study protocol for a randomized controlled trial (MAAS trial). Trials. 2017. PMID: 28859690. doi:10.1186/s13063-017-2118-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。